Published in Gene Therapy Weekly, March 11th, 1996
Cationic lipids have shown the most promise as nonviral DNA delivery systems based on a combination of efficacy, stability, and low toxicity. Lipofectin is a 1:1 mixture of a cationic lipid, DOTMA and a fusogenic lipid, DOPE. The mechanism by which these cationic lipid formulations promote DNA uptake is not completely understood. It has been determined that the cationic component is necessary in any effective gene delivery agent, but the potential exists for something other than a fusogenic lipid to successfully partner with the cationic lipid.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.